Growth in 340B program has not translated to improvements for patients

Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That ’s the most important question policymakers should be asking in any discussion about the 340B program. Unfortunately, this program is essentially a black box with lax reporting requirements and weak oversight – which means there is little to no clear evidence that patients consistently benefit f rom the massive discounts on medicines provided to 340B covered entities.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B 340B Spotlight Source Type: news